Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.59 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.59 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.50 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6944001 | 0.98 | GNAI3 (0.57) | GNAI3GNAO1GNAI1HRH3SPHK1 | |
| SCHEMBL6946272 | 0.90 | GNAI3 (0.52) | GNAI3GNAO1GNAI1HRH3SPHK1 | |
| SCHEMBL2761795 | 0.88 | GNAI3 (0.50) | GNAI3GNAO1GNAI1HRH3SPHK1 | |
| SCHEMBL2761704 | 0.88 | GNAI3 (0.50) | GNAI3GNAO1GNAI1HRH3SPHK1 | |
| Hydrochloric Acid SCHEMBL914047 | 0.86 | GNAI3 (0.53) | GNAI3GNAO1GNAI1HRH3SPHK1 | |
| Hydrochloric Acid SCHEMBL913928 | 0.86 | GNAI3 (0.53) | GNAI3GNAO1GNAI1HRH3SPHK1 | |
| SCHEMBL8168253 | 0.81 | GNAO1 (0.70) | GNAI3GNAO1GNAI1SPHK1 | |
| SCHEMBL13547199 | 0.81 | GNAI3 (0.50) | GNAI3GNAO1GNAI1HRH3SPHK1 | |
| SCHEMBL3966764 | 0.81 | GNAI3 (0.59) | GNAI3GNAO1GNAI1HRH3SPHK1 | |
| SCHEMBL4440646 | 0.80 | GNAI3 (0.42) | GNAI3GNAO1GNAI1HRH3SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
| EP-4066896-A1 | G9A INHIBITOR | RIKEN (JP) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021106988-A1 | G9a INHIBITOR | 杏林製薬株式会社 | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127046-A1 | G9a INHIBITOR | EZH2, BMI1, DOT1L | GNAI3 152/4885GNAO1 536/4885GNAI1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.